BIIB - Biogen Inc

[Spekulatius]

This warrants a further look again imo. The Alzheimer’s drug (Aducanumab) is back on, but the filing is apparently delayed. This is still high risk drug in any case, but I think the rest I’d the franchise cover the current market valuation. Anyone tracking this one closely. I sold the few shares I bought back then but think about buying back in.

[sleepydragon]

I bought a little, to ease my guilt of having bought MO

It has the lowest debt among the bigger bio companies, very profitable, and very high revenue per employee that is comparable to cigarettes companies or Google.
It’s not capital intensive nor labor intensive.

I have no idea if their Alzheimer drug will work though.

[mwtorock]

The risk of BIIB is the competition from biosimilar that is going to sooner or later eat into the high margin revenues, for example anti-CD 20. The stock price is depressed for that reason. If the Alzheimer drug do not get through, BIIB would see decline in revenue.

BIIB is betting big in Neuroscience and spun off unrelated businesses to focus on that. A break through in this area like an approved treatment for Alzheimer would probably give Biogen 10 years dominance like a monopoly. However, so many other companies failed to break through before so people don't give high odds to BIIB.

I own a bit for more than 10 years now probably. The previous management team was great, and created lots of value. I do not really know about this management team, but so far I chose to trust the pick of the previous CEO for succession. The shares do seem to be a little undervalued to me.

[mwtorock]

FDA looks like nodding head on this one:
https://www.fda.gov/media/143503/download?source=news_body_link